GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (CHIX:CALTXs) » Definitions » Short Interest

Calliditas Therapeutics AB (CHIX:CALTXS) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Calliditas Therapeutics AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Calliditas Therapeutics AB's Short Interest

For the Biotechnology subindustry, Calliditas Therapeutics AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calliditas Therapeutics AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Short Interest falls into.


Calliditas Therapeutics AB (CHIX:CALTXS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (CHIX:CALTXs) » Definitions » Short Interest
Comparable Companies
OSTO:GENO OSTO:VICO OSTO:EGTX OSTO:HNSA OSTO:IBT B OSTO:FLUO OSTO:BINV OSTO:XSPRAY OSTO:ONCO OSTO:DMYD B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CALT:USA CALTX:Sweden LC8:Germany LC8A:Germany LC8:Germany
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Website
https://www.calliditas.se
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Calliditas Therapeutics AB (CHIX:CALTXS) Headlines

No Headlines